Researchers unlock mechanism of drug resistance in aggressive breast cancer

Scientists report findings of how triple negative breast cancer cells are able to bypass treatment with trametinib, a U.S. Food and Drug Administration-approved drug that belongs to a class of commonly used anti-cancer drugs called kinase inhibitors. The researchers also reported findings from laboratory models of breast cancer testing a potential treatment approach that could prevent the onset of resistance. (Mehr in: Cancer News — ScienceDaily)